Thyroid associated opthalmopathies

RTW-backed startup Yarrow Bioscience signs autoimmune antibody deal with China’s GenSci

1 month ago talkbio0Tagged anti-TSHR antibody, Antibodies, Autoimmune, Changchun GeneScience Pharmaceutical, China, GenSci, GS-098, Investments, RTW, strategic partnership, Thyroid associated opthalmopathies, Yarrow Bioscience, YB-101

RTW Investments; Yarrow Bioscience; GenSci; Changchun GeneScience Pharmaceutical; autoimmune; antibody; GS-098; YB-101; anti-TSHR antibody; thyroid eye disease; China; ex-China rights; strategic partnership; licensing deal

Viridian Licenses Promising Eye Disease Candidates to Kissei for Japanese Market

6 months ago talkbio0Tagged Antibodies, Biopharma, Clinical Trials, Dosage Forms, Japan, Kissei, Partnership, Thyroid associated opthalmopathies, Veligrotug, Viridian, VRDN-003

Viridian Therapeutics; Kissei Pharmaceutical; veligrotug; VRDN-003; thyroid eye disease; Japan partnership; anti-IGF-1R antibodies; clinical trials; biopharma deal

Viridian’s Veligrotug Demonstrates Efficacy in Second Pivotal Study for Thyroid Eye Disease

1 year ago talkbio0Tagged Antibodies, Clinical Trials, IGF1R protein, human, Phase 3, THRIVE-2, Thyroid associated opthalmopathies, Veligrotug, Viridian

Thyroid Eye Disease, Veligrotug, Viridian Therapeutics, Phase 3 Clinical Trial, THRIVE-2, IGF-1R Antibody

Viridian Therapeutics’ Veligrotug Achieves Positive Topline Results in Phase 3 THRIVE Clinical Trial for Thyroid Eye Disease

1 year ago talkbio0Tagged Antibodies, biopharmaceutical development, Clinical Trials, Phase 3, Success, Thrive, Thyroid associated opthalmopathies, Veligrotug, VRDN-001

Veligrotug (VRDN-001), Thyroid Eye Disease (TED), Phase 3 THRIVE Clinical Trial, Anti-IGF-1R Antibody, Clinical Trial Success, Biopharmaceutical Development